Osteoporosis in postmenopausal women & men at increased risk of fracture. Osteoporosis associated w/ sustained systemic glucocorticoid therapy in women & men at increased risk of fracture.
View Terrosa overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity. Preexisting hypercalcaemia. Metabolic bone diseases including hyperparathyroidism & Paget's disease of bone other than primary osteoporosis of glucocorticoid-induced osteoporosis. Unexplained elevations of alkaline phosphatase. Prior external beam or implant RT to skeleton. Skeletal malignancies or bone metastases. Severe renal impairment.
Transient elevations of serum Ca conc; increased urinary Ca excretion. Increased osteosarcoma incidence w/ long-term administration. Active or recent urolithiasis; episodes of transient orthostatic hypotension. May affect ability to drive & use machines. Moderate renal impairment. Hepatic impairment. Women of childbearing potential should use effective methods of contraception during treatment; premenopausal women. Pregnancy & lactation. Not to be used in childn & adolescents <18 yr or young adult w/ open epiphyses.
Sign Out
